Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.

San Francisco, US
Alector was founded in 2013 and is headquartered in San Francisco, US

Alector Office Locations

Alector has offices in San Francisco and South San Francisco
San Francisco, US (HQ)
953 Indiana St

Alector Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$61.5 m

Latest funding size

$29.5 m

Time since last funding

almost 2 years


Alector's latest funding round in January 2016 was reported to be $29.5 m. In total, Alector has raised $61.5 m

Traffic Overview of Alector

Alector Company Life and Culture

You may also be interested in